Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Davis Steps Down As AAM’s Chief

Francer Will Serve As Interim CEO During Search For Replacement

Executive Summary

The AAM is now searching for new leadership after Chip Davis announced his resignation as president and CEO of the US off-patent industry association.

You may also be interested in...



Lupin’s Sonig Chairs AAM Board

US industry association the AAM has revealed details of its board for 2020, which will be led by Lupin’s Alok Sonig as chair and Sandoz’ Carol Lynch as vice-chair.

AAM Welcomes Passage Of CREATES Act

Industry has welcomed the passage of the CREATES Act in the US, which is aimed at curbing originator attempts to deny access to samples by abusing FDA safety programs.

Industry Delighted By ‘Fixed’ USMCA

Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.

Related Content

Topics

UsernamePublicRestriction

Register

GB149603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel